Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Receives Average Rating of “Buy” from Analysts

Shares of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) have been given an average recommendation of “Buy” by the seven research firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $15.40.

A number of research analysts recently commented on FOMX shares. Cowen set a $30.00 price target on Foamix Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, September 23rd. Zacks Investment Research upgraded shares of Foamix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 target price (up from $10.00) on shares of Foamix Pharmaceuticals in a report on Monday, October 21st.

NASDAQ:FOMX traded down $0.10 during trading hours on Tuesday, reaching $2.87. 51,068 shares of the company were exchanged, compared to its average volume of 1,250,947. The business has a 50 day moving average of $3.33 and a 200 day moving average of $2.89. Foamix Pharmaceuticals has a 1-year low of $1.97 and a 1-year high of $4.48. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.72 and a quick ratio of 5.72. The company has a market capitalization of $181.61 million, a P/E ratio of -1.69 and a beta of 1.53.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Monday, November 11th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.07). Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 100.58%. As a group, equities research analysts anticipate that Foamix Pharmaceuticals will post -1.66 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the company. Royal Bank of Canada lifted its position in shares of Foamix Pharmaceuticals by 76.5% during the 2nd quarter. Royal Bank of Canada now owns 13,694 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 5,937 shares during the last quarter. Stifel Financial Corp bought a new stake in shares of Foamix Pharmaceuticals during the 3rd quarter valued at approximately $54,000. grace capital increased its position in Foamix Pharmaceuticals by 86.9% during the 2nd quarter. grace capital now owns 20,000 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 9,300 shares in the last quarter. Worth Venture Partners LLC increased its position in Foamix Pharmaceuticals by 75.0% during the 2nd quarter. Worth Venture Partners LLC now owns 23,627 shares of the specialty pharmaceutical company’s stock worth $56,000 after purchasing an additional 10,127 shares in the last quarter. Finally, Delek Group Ltd. lifted its stake in Foamix Pharmaceuticals by 23.2% in the 2nd quarter. Delek Group Ltd. now owns 62,437 shares of the specialty pharmaceutical company’s stock valued at $145,000 after purchasing an additional 11,741 shares during the last quarter. Institutional investors own 47.29% of the company’s stock.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.

Further Reading: What are the qualifications of a portfolio manager?

Analyst Recommendations for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.